CELC at a glance
Celcuity Inc. (CELC, SEC CIK 1603454) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as October 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Celcuity Inc. (CELC) shares worth $1.2 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by BAKER BROS. ADVISORS LP on July 14, 2026 of 261,368 shares at $102.50 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 29 funds
- $1.2B · +0 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Quarterly product revenue $0, unchanged YoY, as REVTORPYK shipments began September 30, 2026
- Net loss $73.3M vs $43.8M YoY, operating loss $77.3M vs $42.8M
- Worst cost trend: SG&A $39.8M, up 220% YoY, driven by commercialization spending
- Cash, equivalents and short-term investments $642.7M; operating cash use $176.7M through nine months
- Cash runway expected through 2029, with commercialization and clinical-development spending increasing
Risk Factors
- New regulatory risk: August 2026 sNDA for PIK3CA-mutated patients may face delay, rejection, narrower labeling, or additional data requirements
- Regulatory and compliance risk: FDA noncompliance could trigger recalls, approval withdrawal, fines, injunctions, or criminal penalties
- Market risk: REVTORPYK faces competition from alpelisib, capivasertib, everolimus, and endocrine regimens
- Pricing and reimbursement risk: Proposed Medicare MFN rebate models could begin January 1, 2027
- Intellectual-property risk: Generic competition could follow patent challenges and substantially reduce REVTORPYK revenue
AI summary of the CELC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Celcuity announced financial results for the quarter ended September 30, 2026
- Full revenue, earnings and cash-flow details are in Exhibit 99.1, the accompanying results release
Item EX-99.1: Item EX-99.1
- REVTORPYK launch gaining access: 91% of U.S. commercial and Medicare lives covered, while 78% of 36 strategic accounts have ordered
- Early reach broad but revenue absent: shipments began September 30, yet no product revenue recognized in Q3
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expanded from 8 to 9 directors, adding David W. Gryska through the 2027 Annual Meeting
- Gryska qualifies as Nasdaq and SEC independent director
Item EX-99.1: Item EX-99.1
- David Gryska appointed to Celcuity’s Board, adding over 35 years of life sciences strategic and financial leadership
- Former CFO of Incyte and Celgene, strengthening oversight as Celcuity transitions to commercial operations
Item 7.01: Regulation FD Disclosure
- Board appointment announcement for Mr. Gryska, adding a new director to Celcuity’s governance structure
- Audit Committee and Compensation Committee assignments, expanding his oversight responsibilities
Item 8.01: Other Events
- REVTORPYK commercially available in the U.S. for eligible HR+/HER2- advanced breast cancer patients
- Indicated after progression following at least one metastatic-setting endocrine therapy line
Item EX-99.1: Item EX-99.1
- REVTORPYK became commercially available in the U.S. on September 30, 2026, initiating Celcuity’s first product launch
- FDA-approved for HR+/HER2- advanced breast cancer without detected PIK3CA mutation after at least one metastatic endocrine-therapy line
Item 7.01: Regulation FD Disclosure
- REVTORPYK (gedatolisib) now commercially available in the U.S. for eligible breast cancer patients
- Indication: HR+, HER2-, locally advanced or metastatic disease after endocrine-therapy progression
AI summaries of CELC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CELC
Don't miss the next CELC filing
- Alerts as it files. A push when CELC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CELC, by share count.
- Ask anything. An AI agent that reads every CELC filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Furcht Leo | M | Oct 7, 2026 | 250 | $7.60 |
| Furcht Leo | M | Oct 7, 2026 | 250 | - |
| GRYSKA DAVID W | A | Oct 1, 2026 | 893 | - |
| Laing Lance G. | A | Aug 14, 2026 | 20,000 | - |
| Sullivan Brian F. | A | Aug 14, 2026 | 80,000 | - |
| Sullivan Brian F. | A | Aug 14, 2026 | 120,000 | - |
| Hahne Vicky | A | Aug 14, 2026 | 10,000 | - |
| Laing Lance G. | A | Aug 14, 2026 | 10,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$66.2M | -$113.3M | -$172.2M |
| Net Income | -$63.8M | -$111.8M | -$177.0M |
| Balance Sheet | |||
| Total Assets | - | $245.1M | $466.6M |
| Equity | $139.8M | $115.6M | $100.6M |
| ROE | -45.6% | -96.7% | -176.1% |
| Per Share | |||
| EPS | $-2.69 | $-2.83 | $-3.79 |
| Cash Flow | |||
| Operating CF | -$53.8M | -$83.5M | -$153.3M |
| CapEx | $98K | $250K | $249K |
Source: XBRL data in Celcuity Inc. (CELC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CELC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 29 | $1.20B |
| Q2 2026 | 29 | $1.48B |
| Q1 2026 | 31 | $1.35B |
| Q4 2025 | 28 | $1.24B |
| Q3 2025 | 28 | $518.7M |
| Q2 2025 | 22 | $104.3M |
| Q1 2025 | 17 | $58.4M |
| Q4 2024 | 14 | $61.3M |
- Bank of America Corp+238.1K (+16%)
- Morgan Stanley+198.4K (+15%)
- Franklin Resources+194.8K (+65%)
- BlackRock+158.8K (+5%)
- Goldman Sachs Group+132.9K (+15%)
- T. Rowe Price Group−538.5K (-52%)
- Citigroup−75.7K (-75%)
- Vanguard Portfolio Management LLC−24.5K (-6%)
- Wells Fargo & Co−18.2K (-16%)
- D.E. Shaw & Co−7.9K (-26%)
- Citadel Advisors LLC+600.4K
- Two Sigma Investments+457.6K
- Millennium Management+66.7K
- TOMPKINS FINANCIAL CORP+125
- FMR LLC (Fidelity)−549.0K
- Ameriprise Financial−15.3K
- M&T Bank−3.6K
- Marex Group plc−2.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 198 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CELC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 9, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 8-K | Oct 2, 2026 | - | Analysis | - |
| 8-K | Sep 30, 2026 | - | Analysis | - |
| 8-K | Aug 26, 2026 | - | Analysis | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| SC 13G | Aug 11, 2026 | - | - | |
| 4 | Jul 16, 2026 | - | - | - |
| SC 13G | Jul 16, 2026 | - | - | |
| 8-K | Jul 15, 2026 | - | Analysis | - |
| 8-K | Jul 15, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - |
Related Health Care companies
- CDNA · CareDx, Inc.Services-Medical Laboratories
- CSTL · CASTLE BIOSCIENCES INCServices-Medical Laboratories
- FTRE · Fortrea Holdings Inc.Services-Medical Laboratories
- FLGT · Fulgent Genetics, Inc.Services-Medical Laboratories
- GRAL · GRAIL, Inc.Services-Medical Laboratories
- GH · Guardant Health, Inc.Services-Medical Laboratories
- LH · LabcorpServices-Medical Laboratories
- NTRA · Natera IncServices-Medical Laboratories
CELC SEC filings: frequently asked questions
Which institutions hold CELC stock?
As of September 30, 2026, the largest Celcuity Inc. (CELC) holders among the 13F filers tracked by SignalX were BlackRock ($252.7 million), State Street Corp ($163.5 million), Vanguard Capital Management LLC ($154.4 million), Bank of America Corp ($135.9 million), Morgan Stanley ($121.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did CELC report in its latest 8-K?
Celcuity Inc. (CELC) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Celcuity announced financial results for the quarter ended September 30, 2026.
What are the latest CELC SEC filings?
Celcuity Inc. (CELC) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on October 9, 2026.
What is CELC's SEC CIK number?
Celcuity Inc. (CELC)'s SEC Central Index Key (CIK) is 1603454. EDGAR lists every CELC filing under that number.
Ask anything about CELC
The research agent reads CELC's filings, financials, insider trades and 13F holders, then answers with sources.